← feed

Is NCT01685892 results overdue?

Yes — results are overdue. Primary completion was 2018-05-21; the FDAAA-801 reporting deadline (2019-05-21) passed 2634 days ago and no results are posted on ClinicalTrials.gov.

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

NCT IDNCT01685892 ↗
SponsorGenentech, Inc. (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2018-05-21 (ACTUAL)
Reporting deadline2019-05-21 (completion + 365d)
Days overdue2634
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 77cb0790fea466e9… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT01685892. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →